EP Patent

EP1438044A1 — Bis-heteroaryl alkanes as therapeutic agents

Assigned to vTv Therapeutics LLC · Expires 2004-07-21 · 22y expired

What this patent protects

This invention provides compounds (I) which are useful as inhibitors of protein tyrosine phosphatases (PTPases). As inhibitors of PTPases the compounds of the invention are useful for the management, treatment, control and adjunct treatment of diseases in mammals mediated by PTPa…

USPTO Abstract

This invention provides compounds (I) which are useful as inhibitors of protein tyrosine phosphatases (PTPases). As inhibitors of PTPases the compounds of the invention are useful for the management, treatment, control and adjunct treatment of diseases in mammals mediated by PTPase activity. Such diseases include type I diabetes, type II diabetes, immune dysfunction, AIDS, autoimmunity, glucose intolerance, obesity, cancer, psoriasis, allergic diseases, infectious diseases, inflammatory diseases, diseases involving the modulated synthesis of growth hormone or the modulated synthesis of growth factors or cytokines which affect the production of growth hormone, or Alzheimer's disease. Wherein R1 and R2 independently comprise (a) or (b).

Drugs covered by this patent

Patent Metadata

Patent number
EP1438044A1
Jurisdiction
EP
Classification
—
Expires
2004-07-21
Drug substance claim
No
Drug product claim
No
Assignee
vTv Therapeutics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.